EP Patent

EP3492080A1 — Dosing regimen for sedation with cns 7056 (remimazolam)

Assigned to Paion UK Ltd · Expires 2019-06-05 · 7y expired

What this patent protects

The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056, wherein CNS 7056 is given in a fixed dose of 2 to 10 mg.

USPTO Abstract

The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056, wherein CNS 7056 is given in a fixed dose of 2 to 10 mg.

Drugs covered by this patent

Patent Metadata

Patent number
EP3492080A1
Jurisdiction
EP
Classification
—
Expires
2019-06-05
Drug substance claim
No
Drug product claim
No
Assignee
Paion UK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.